© 2017 Angiogenex. All rights reserved.

Patent Portfolio

The Company’s proprietary assets, its anti-Id drugs are described in the form of issued and pending US and world-wide patents described on the following table. In addition the Company has exclusive rights to  novel anti- ID molecules that are the subject of unpublished Pending Patent Applications.

Methods and compositions of targeted drug development 
WO 2011085126 A2